Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. Mapk14b is one of the four p38 MAPKs which play an important role in the cascades of cellular responses evoked by extracellular stimuli such as pro-inflammatory cytokines or physical stress leading to direct activation of transcription factors. Accordingly, p38 MAPKs phosphorylate a broad range of proteins and it has been estimated that they may have approximately 200 to 300 substrates each.
Some of the targets are downstream kinases which are activated through phosphorylation and further phosphorylate additional targets (By similarity)
The TXY motif contains the threonine and tyrosine residues whose phosphorylation activates the MAP kinases
Click a pathway to open the interactive Reactome viewer.
Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to MAPK14, aggregated across our SSL data sources. Click any partner node to view that gene’s page.
Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.
Total Trials Found: 34
| NCT ID | Condition | Brief Title | Phase | Status |
|---|---|---|---|---|
| NCT05765955 | Influenza, Human | Effects of p38 MAPK Inhibitor POLB 001 on in Vivo LPS Challenge Responses | PHASE1 | COMPLETED |
| NCT02364206 | Adult Glioblastoma | Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma | PHASE1, PHASE2 | COMPLETED |
| NCT00390845 | Pain, Neuropathic | P38 Mitogen-activated Protein (Map) Kinase Inhibitor (SB-681323)Study In Patients With Neuropathic Pain | PHASE2 | COMPLETED |
| NCT02322853 | Postmenopausal, Metastatic Breast Cancer | A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors | PHASE2 | TERMINATED |
| NCT04001517 | Dementia With Lewy Bodies (DLB) | Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies | PHASE2 | COMPLETED |
| NCT04470050 | Opioid Withdrawal | Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal | PHASE1, PHASE2 | COMPLETED |
| NCT02423200 | Alzheimer's Disease | Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD | PHASE2 | COMPLETED |
| NCT06815965 | Dementia With Lewy Bodies (DLB) | A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies | PHASE2 | COMPLETED |
| NCT00976560 | Depressive Disorder, Major | Clinical Study to Test a New Drug to Treat Major Depression | PHASE2 | COMPLETED |
| NCT00087867 | Multiple Myeloma | Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma | PHASE2 | COMPLETED |